Table 2 Hematopoietic reconstitution.

From: Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation

 

rhTPO group (n = 26)

Control group (n = 14)

p value

Median number of reinfused CD34 + cells, ×106/kg (range)

3.619 (1.9–10.5)

3.557 (1.49–10.48)

0.934

Median number of RBC infusions, units (range)

0.23 (0–3.5)

0.0 (0–0)

0.326

Median number of PLT infusions, units (range)

1.615 (0–3)

1.5 (0–4)

0.721

Median time to ANC > 0.5 × 109/L, days (range)

10.92 (9–12)

11.14 (10–13)

0.405

Median time to PLTc > 20 × 109/L, days (range)

11.5 (8–16)

11.36 (9–14)

0.776

Median time to PLTc > 50 × 109/L, days (range)

13.96 (9–17)

14 (10–19)

0.956

PLTc > 50 × 109/L on day 15 after ASCT, n (%)

19 (73.1%)

9 (64.3%)

0.720

Duration of neutrophil deficiency, days (range)

6.269 (4–9)

6 (4–9)

0.504

Median days on parenteral antibiotics (range)

9.885 (0–20)

6.286 (3–12)

0.002

Median days of hospitalization (range)

27.08 (16–41)

25.07 (21–31)

0.193

Median hospitalization cost, RMB (range)

73,846 (38,532–116,275)

54,136 (43,427–68,619)

< 0.001

  1. rhTPO recombinant human thrombopoietin, RBC red blood cell, PLT platelet, ANC absolute neutrophil count, PLTc platelet count, ASCT autologous stem cell transplantation. Significant values are in bold.
Back to article page